These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 11034950)

  • 1. Effects of dopamine beta-hydroxylase inhibition with nepicastat on the progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure.
    Sabbah HN; Stanley WC; Sharov VG; Mishima T; Tanimura M; Benedict CR; Hegde S; Goldstein S
    Circulation; 2000 Oct; 102(16):1990-5. PubMed ID: 11034950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure.
    Rastogi S; Sharov VG; Mishra S; Gupta RC; Blackburn B; Belardinelli L; Stanley WC; Sabbah HN
    Am J Physiol Heart Circ Physiol; 2008 Nov; 295(5):H2149-55. PubMed ID: 18820026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure.
    Suzuki G; Morita H; Mishima T; Sharov VG; Todor A; Tanhehco EJ; Rudolph AE; McMahon EG; Goldstein S; Sabbah HN
    Circulation; 2002 Dec; 106(23):2967-72. PubMed ID: 12460880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective matrix metalloproteinase inhibition attenuates progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure.
    Morita H; Khanal S; Rastogi S; Suzuki G; Imai M; Todor A; Sharov VG; Goldstein S; O'Neill TP; Sabbah HN
    Am J Physiol Heart Circ Physiol; 2006 Jun; 290(6):H2522-7. PubMed ID: 16428338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction.
    Sabbah HN; Shimoyama H; Kono T; Gupta RC; Sharov VG; Scicli G; Levine TB; Goldstein S
    Circulation; 1994 Jun; 89(6):2852-9. PubMed ID: 8205701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic Therapy With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure.
    Sabbah HN; Gupta RC; Kohli S; Wang M; Hachem S; Zhang K
    Circ Heart Fail; 2016 Feb; 9(2):e002206. PubMed ID: 26839394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Catecholamine modulatory effects of nepicastat (RS-25560-197), a novel, potent and selective inhibitor of dopamine-beta-hydroxylase.
    Stanley WC; Li B; Bonhaus DW; Johnson LG; Lee K; Porter S; Walker K; Martinez G; Eglen RM; Whiting RL; Hegde SS
    Br J Pharmacol; 1997 Aug; 121(8):1803-9. PubMed ID: 9283721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of long-term therapy with bosentan on the progression of left ventricular dysfunction and remodeling in dogs with heart failure.
    Mishima T; Tanimura M; Suzuki G; Todor A; Sharov VG; Goldstein S; Sabbah HN
    J Am Coll Cardiol; 2000 Jan; 35(1):222-9. PubMed ID: 10636284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine-beta-hydroxylase inhibition: a novel sympatho-modulatory approach for the treatment of congestive heart failure.
    Hegde SS; Friday KF
    Curr Pharm Des; 1998 Dec; 4(6):469-79. PubMed ID: 10197057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular effects of nepicastat (RS-25560-197), a novel dopamine beta-hydroxylase inhibitor.
    Stanley WC; Lee K; Johnson LG; Whiting RL; Eglen RM; Hegde SS
    J Cardiovasc Pharmacol; 1998 Jun; 31(6):963-70. PubMed ID: 9641484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the AT1-receptor antagonist eprosartan on the progression of left ventricular dysfunction in dogs with heart failure.
    Suzuki G; Mishima T; Tanhehco EJ; Sharov VG; Todor A; Rostogi S; Gupta RC; Chaudhry PA; Anagnostopoulos PV; Nass O; Goldstein S; Sabbah HN
    Br J Pharmacol; 2003 Jan; 138(2):301-9. PubMed ID: 12540520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of chronic neutral endopeptidase inhibition on the progression of left ventricular dysfunction and remodeling in dogs with moderate heart failure.
    Mishima T; Tanimura M; Suzuki G; Todor A; Sharov VG; Tanhehco EJ; Goldstein S; Sabbah HN
    Cardiovasc Drugs Ther; 2002 May; 16(3):209-14. PubMed ID: 12374898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic monotherapy with rosuvastatin prevents progressive left ventricular dysfunction and remodeling in dogs with heart failure.
    Zacà V; Rastogi S; Imai M; Wang M; Sharov VG; Jiang A; Goldstein S; Sabbah HN
    J Am Coll Cardiol; 2007 Aug; 50(6):551-7. PubMed ID: 17678740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ventricular remodeling: insights from pharmacologic interventions with angiotensin-converting enzyme inhibitors.
    Goldstein S; Sharov VG; Cook JM; Sabbah HN
    Mol Cell Biochem; 1995 Jun 7-21; 147(1-2):51-5. PubMed ID: 7494555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic therapy with a partial adenosine A1-receptor agonist improves left ventricular function and remodeling in dogs with advanced heart failure.
    Sabbah HN; Gupta RC; Kohli S; Wang M; Rastogi S; Zhang K; Zimmermann K; Diedrichs N; Albrecht-Küpper BE
    Circ Heart Fail; 2013 May; 6(3):563-71. PubMed ID: 23564604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure.
    Sabbah HN; Chandler MP; Mishima T; Suzuki G; Chaudhry P; Nass O; Biesiadecki BJ; Blackburn B; Wolff A; Stanley WC
    J Card Fail; 2002 Dec; 8(6):416-22. PubMed ID: 12528095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction.
    Udelson JE; Feldman AM; Greenberg B; Pitt B; Mukherjee R; Solomon HA; Konstam MA
    Circ Heart Fail; 2010 May; 3(3):347-53. PubMed ID: 20299607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Intravenous Infusion of Vepoloxamer on Left Ventricular Function in Dogs with Advanced Heart Failure.
    Sabbah HN; Zhang K; Gupta RC; Emanuele M
    Cardiovasc Drugs Ther; 2020 Apr; 34(2):153-164. PubMed ID: 32146638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term pharmacological activation of PPARgamma does not prevent left ventricular remodeling in dogs with advanced heart failure.
    Suzuki G; Khanal S; Rastogi S; Morita H; Mishima T; Anagnostopoulos PV; Nass O; Sharov VG; Tanhehco EJ; Goldstein S; Sabbah HN
    Cardiovasc Drugs Ther; 2007 Feb; 21(1):29-36. PubMed ID: 17294127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atenolol is inferior to metoprolol in improving left ventricular function and preventing ventricular remodeling in dogs with heart failure.
    Zacà V; Rastogi S; Mishra S; Wang M; Sharov VG; Gupta RC; Goldstein S; Sabbah HN
    Cardiology; 2009; 112(4):294-302. PubMed ID: 18832825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.